CD200 MFI < 189.5 was still capable of segregating a group of patients displaying relatively short TTT in CLL patients with early stage disease (Binet A), mutated IGHV status, normal TP53 or CD38 < 30% (Figure 7). The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.